A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Conditions

• Squamous Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ZEN003694 — DRUG
  ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle

Study Details

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.

Key Dates

Start date

Nov 1, 2022

Status verified

Mar 2026

Primary completion

Nov 30, 2027

Completion

Nov 30, 2027

Study Design

Enrollment

13 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: ZEN003694
  All patients enrolled on the study will undergo treatment with ZEN003694 60mg po qd on a 5 days on/2 days off schedule in an every 21-day cycle. All assessments, including drug dosing, have a window of +/- 7 days unless otherwise noted.

Primary Outcome Measure

overall response rate (ORR) [ Time Frame: 2 years ]

Central Contacts

• Paul Paik, MD
  646-608-3759
  [email protected]
• Mark Kris, MD
  646-608-3914

Locations (7)

Find similar trials in Basking Ridge, NJ